CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,193,340 | +65.0% | 141,000 | 0.0% | 5.38% | +146.8% |
| Q2 2023 | $2,540,820 | +12.2% | 141,000 | 0.0% | 2.18% | +16.6% |
| Q1 2023 | $2,264,460 | -12.2% | 141,000 | 0.0% | 1.87% | +0.2% |
| Q4 2022 | $2,580,300 | -6.8% | 141,000 | 0.0% | 1.87% | +13.7% |
| Q3 2022 | $2,769,000 | +5.3% | 141,000 | 0.0% | 1.64% | -3.6% |
| Q2 2022 | $2,630,000 | -15.0% | 141,000 | 0.0% | 1.70% | +11.7% |
| Q1 2022 | $3,095,000 | -22.7% | 141,000 | 0.0% | 1.52% | +5.1% |
| Q4 2021 | $4,006,000 | +35.0% | 141,000 | 0.0% | 1.45% | +69.5% |
| Q3 2021 | $2,968,000 | -93.3% | 141,000 | 0.0% | 0.86% | -92.5% |
| Q2 2021 | $44,282,000 | +1955.8% | 141,000 | 0.0% | 11.37% | +2168.7% |
| Q1 2021 | $2,154,000 | +8.2% | 141,000 | 0.0% | 0.50% | +8.9% |
| Q4 2020 | $1,990,000 | -9.9% | 141,000 | 0.0% | 0.46% | -48.3% |
| Q3 2020 | $2,209,000 | -10.6% | 141,000 | 0.0% | 0.89% | +25.5% |
| Q2 2020 | $2,470,000 | +19.2% | 141,000 | 0.0% | 0.71% | +14.4% |
| Q1 2020 | $2,073,000 | -41.4% | 141,000 | 0.0% | 0.62% | -19.4% |
| Q4 2019 | $3,538,000 | +66.8% | 141,000 | 0.0% | 0.77% | +19.8% |
| Q3 2019 | $2,121,000 | -49.4% | 141,000 | -15.9% | 0.64% | -42.9% |
| Q2 2019 | $4,193,000 | +9.9% | 167,700 | 0.0% | 1.12% | +7.5% |
| Q1 2019 | $3,817,000 | -24.1% | 167,700 | 0.0% | 1.05% | -24.2% |
| Q4 2018 | $5,029,000 | +4.7% | 167,700 | 0.0% | 1.38% | +57.9% |
| Q3 2018 | $4,805,000 | – | 167,700 | – | 0.87% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |